NCT05291689: A reported trial by Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT05291689 |
|---|---|
| Title | A Phase 2a, Open-label, Single-arm Study to Evaluate the Efficacy, Safety, and Tolerability of MORF-057 in Adults With Moderately to Severely Active Ulcerative Colitis (EMERALD-1) |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | May 24, 2022 |
| Completion date | Oct. 18, 2023 |
| Required reporting date | Oct. 17, 2024, midnight |
| Actual reporting date | Oct. 18, 2024 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |